Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Ates cash on hand is dropping 8-12 mill a quarter

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jan 11, 2022 7:50pm

176 Views

Post# 34306195

RE:Ates cash on hand is dropping 8-12 mill a quarter

Stutters wrote:
then they will have to raise money

I estimate it will work out to a spend of $2.5M per month.
Add something back for the sale of CITA - let's call it $7.5M (for now).

That would get us well into 2024 so they likely wouldn't be contemplating going to markets until Q3-Q4 of 2024 - world away.

Question is ... are they willing to up the development work at Dalriada or are they planning on going slowly ? I'm betting they ramp up Dalriada work on a successful IBD drug selection.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China